Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minExpanding
5 minExpanding
Daily trend turns down below $357.98
Key levels
Resistance$360.30
Resistance$357.98
Latest news & SEC filings
No headlines in the last 90 days.
Karyopharm Therapeutics is a pharmaceutical company that discovers and develops drugs for cancer and other serious diseases. Its main focus is on oral compounds that target nuclear export, a cellular process involved in disease. The company sells its products to healthcare providers and patients, primarily in the United States, and also works with partners in other regions.
Based on the company's 10-K filed Feb 13, 2026.
Nasdaq · Healthcare
SEPT Low Target
$4.25
SEPT Mid Target
$5.00
SEPT High Target
$5.75
Analyst Consensus
$5.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for KPTI.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$5.00
44
Moat Score
NARROW
2/9
Piotroski Score
-24.0
Altman Z-Score
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
ACCUMULATING
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Abate Kristin | officer | Sale | 19 | $38.38 | Sep 1, 2026 |
| Su Zhen | director | Buy | 15,508 | - | May 21, 2026 |
| Oliger Christy J. | director | Buy | 15,508 | - | May 21, 2026 |
| Schor Chen | director | Buy | 15,508 | - | May 21, 2026 |
| Greene Barry E | director | Buy | 15,508 | - | May 21, 2026 |
| PAKIANATHAN DEEPIKA | director | Buy | 15,508 | - | May 21, 2026 |
| BOHLIN GAREN G | director | Buy | 15,508 | - | May 21, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
0.6%
3yr Revenue CAGR
-2.4%
EPS Growth YoY
-28.07%
FCF Growth YoY
41.0%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for KPTI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 24:59:49 | $0.02 | 27,000 | $$435 | SELL |
| 24:59:41 | $0.02 | 4,000 | $$64 | SELL |
| 24:59:38 | $0.02 | 1,000 | $$16 | SELL |
| 24:59:34 | $0.02 | 6,500 | $$105 | BUY |
| 24:59:27 | $0.02 | 1,500 | $$24 | BUY |
5 dark pool trades shown · $$644 preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Karyopharm Therapeutics Inc. (KPTI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Karyopharm Therapeutics Inc. (KPTI) is at $0.02, down 56.50% (-$0.02) at the Nov 10, 2026 close.
The average analyst price target for KPTI is $5.00, ranging from $3 to $7, based on 2 analysts. Latest: Piper Sandler maintains on Jul 31, 2026.
Analyst ratings for KPTI: 0 Buy, 3 Hold, 1 Sell — consensus Hold.
KPTI does not currently pay a dividend.
Resistance: $357.98, $360.30, $366.00.
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.